WuBlockchain
NewLimit, a longevity biotech startup co-founded by Coinbase CEO Brian Armstrong, has raised a $435 million Series C led by Founders Fund, with Thrive Capital, Greenoaks and Quiet Capital joining as new investors and Kleiner Perkins and Eli Lilly Ventures returning.
The company said the capital will fund its push to advance its first age-reprogramming drug candidate into human trials next year — the first clinical-stage step in a program that has, until now, been purely preclinical.
Why it matters
NewLimit sits in a narrow category: startups applying partial cellular reprogramming — the technique of dialing back cells' epigenetic age without erasing their identity — to treat age-related disease. The field is drawing sustained capital from a mix of crypto-origin founders, biotech-focused VCs, and large pharma corporate arms, signalling that longevity is graduating from philanthropic funding into conventional venture-scale rounds.
Market impact
Eli Lilly Ventures' continued participation is the most concrete signal: a top-tier pharma corporate investor doubling down on a reprogramming approach that is still pre-IND. For readers tracking the broader biotech funding environment, a $435M Series C at this stage is a strong vote of confidence in reprogramming as a tractable path to clinic, and sets a higher bar for the next cohort of longevity startups raising in 2026.
Frequently asked questions
-
What does NewLimit do?
NewLimit is a longevity biotech startup applying partial cellular reprogramming — dialing back cells' epigenetic age without erasing their identity — to develop drugs for age-related disease. Its first candidate is slated to enter human trials in 2026.
-
Who led NewLimit's $435M Series C?
Founders Fund led the round. New investors Thrive Capital, Greenoaks and Quiet Capital joined, with existing backers Kleiner Perkins and Eli Lilly Ventures also participating.
-
Who is Brian Armstrong's role at NewLimit?
Brian Armstrong, the CEO of Coinbase, is a co-founder of NewLimit. He is not involved in day-to-day operations but has been a public backer of the company's mission to extend human healthspan.
-
Why is Eli Lilly Ventures' participation significant?
A top-tier pharma corporate investor doubling down on a reprogramming approach that is still pre-IND signals mainstream pharma conviction in the modality. It also gives NewLimit a credible partner as its first candidate moves toward clinical trials.
-
What is cellular reprogramming?
Cellular reprogramming is a technique that uses Yamanaka-style factors to reset a cell's epigenetic markers — effectively dialing back its biological age — without fully converting it back into a stem cell. NewLimit's approach is partial, meaning cells keep their original identity while shedding accumulated…
CoinTelegraph
TheBlock
Crypto Rank News
CoinDesk
Crypto News
Lookonchain
CryptoSlate